Capital expansion Samsung Biologics is actively pursuing large-scale financing and asset expansion, including a US$2.2 billion rights offering to fund acquisitions and new production campuses in Incheon and Texas, signaling readiness for aggressive capacity growth and potential CDMO partnerships to support scale-up projects.

Global campus growth Major capacity buildouts across South Korea and the United States, including a 256,000-liter Texas facility and multiple Songdo campuses, create opportunities for end-to-end biologics development and manufacturing collaborations, especially for clients seeking integrated global supply chains.

Peptide manufacturing push Entry into the peptide CDMO space through acquisitions positions Samsung Biologics as a broader manufacturing partner and a potential supplier for peptide-based therapeutics, offering cross-sell opportunities to existing biologics clients and targeting peptide-focused biotech companies.

Biosimilars leadership As a leading biosimilars CDMO with one of the largest construction programs, Samsung Biologics can appeal to biosimilar developers and sponsors seeking scale, regulatory maturity, and proven throughput to accelerate time-to-market for biosimilar portfolios.

Regulatory and capacity scale With proven regulatory approvals and the fastest throughput combined with expanding facilities, there is a strong value proposition for clients needing rapid development, scalable manufacturing capacity, and risk mitigation through a single integrated partner across development and commercial stages.